Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Treatment of invasive fungal infections

Treatment of invasive fungal infections Invasive fungal infections are a major threat for haemato-oncologic patients. The diagnosis is challenging, but an early and adequate therapy is crucial for survival. Echinocandins are suggested for initial treatment of critically ill patients with invasive candidiasis. Fluconazole is justified when the condition is stable and resistance is infrequent i. e. the incidence for Candida glabrata and Candida krusei is low. For invasive aspergillosis voriconazole is usually the drug of choice. Amphotericin B preparations, particularly the lipid formulations are adequate alternatives for invasive aspergillosis and for invasive candidiasis. First-line treatment of zygomycosis is performed with an amphotericin B preparation, whereas posaconazole is licensed for salvage therapy or oral step down treatment. Liposomal amphotericin B, amphotericin B colloidal dispersion and caspofungin are licensed for empirical anti-fungal treatment in persistent fever and neutropenia. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Treatment of invasive fungal infections

Loading next page...
 
/lp/springer-journals/treatment-of-invasive-fungal-infections-nVgOaDjU4e
Publisher
Springer Journals
Copyright
Copyright © 2011 by Springer-Verlag
Subject
Medicine & Public Health; Medicine/Public Health, general; Oncology
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-011-0290-3
Publisher site
See Article on Publisher Site

Abstract

Invasive fungal infections are a major threat for haemato-oncologic patients. The diagnosis is challenging, but an early and adequate therapy is crucial for survival. Echinocandins are suggested for initial treatment of critically ill patients with invasive candidiasis. Fluconazole is justified when the condition is stable and resistance is infrequent i. e. the incidence for Candida glabrata and Candida krusei is low. For invasive aspergillosis voriconazole is usually the drug of choice. Amphotericin B preparations, particularly the lipid formulations are adequate alternatives for invasive aspergillosis and for invasive candidiasis. First-line treatment of zygomycosis is performed with an amphotericin B preparation, whereas posaconazole is licensed for salvage therapy or oral step down treatment. Liposomal amphotericin B, amphotericin B colloidal dispersion and caspofungin are licensed for empirical anti-fungal treatment in persistent fever and neutropenia.

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Oct 13, 2011

References